REPLIGEN CORP (RGEN) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2020-12-31..
Gross margin
Overview →Financial period ending 2020-12-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2020-12-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 209.63M USD | Gross Profit |
| Revenue | (m) | |
| Cost of products and services | 156.63M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2020-12-31 | $209.63M | (m) | $156.63M | (m) |
| 2020-09-30 | $188.49M | (m) | $138.59M | (m) |
| 2020-06-30 | $172.08M | (m) | $130.39M | (m) |
| 2020-03-31 | $161.47M | (m) | $124.24M | (m) |
| 2019-12-31 | $151.15M | (m) | $119.10M | (m) |
| 2019-09-30 | $140.14M | (m) | $112.57M | (m) |
| 2019-06-30 | $129.47M | (m) | $103.33M | (m) |
| 2019-03-31 | $116.13M | (m) | $93.71M | (m) |
| 2018-12-31 | $107.50M | (m) | $86.53M | (m) |
| 2018-09-30 | $101.63M | (m) | $82.08M | (m) |
| 2018-06-30 | $90.87M | (m) | $79.88M | (m) |
| 2018-03-31 | (m) | $155.48M | (m) | (m) |
| 2017-12-31 | (m) | $141.24M | (m) | (m) |
| 2017-09-30 | (m) | $125.22M | (m) | (m) |
| 2017-06-30 | (m) | $113.32M | (m) | (m) |
| 2017-03-31 | (m) | $110.04M | (m) | (m) |
| 2016-12-31 | (m) | $104.54M | (m) | (m) |
| 2016-09-30 | (m) | $100.39M | (m) | (m) |
| 2016-06-30 | (m) | $95.53M | (m) | (m) |
| 2016-03-31 | (m) | $87.81M | (m) | (m) |
| 2015-12-31 | (m) | $83.54M | (m) | (m) |
| 2015-09-30 | (m) | $78.48M | (m) | (m) |
| 2015-06-30 | (m) | $73.94M | (m) | (m) |
| 2015-03-31 | (m) | $68.04M | (m) | (m) |
| 2014-12-31 | (m) | $63.55M | (m) | (m) |
| 2014-09-30 | (m) | $62.54M | (m) | (m) |
| 2014-06-30 | (m) | $66.08M | (m) | (m) |
| 2014-03-31 | (m) | $68.04M | (m) | (m) |
| 2013-12-31 | (m) | $68.17M | (m) | (m) |
| 2013-09-30 | (m) | $71.60M | (m) | (m) |
| 2013-06-30 | (m) | $67.88M | (m) | (m) |
| 2013-03-31 | (m) | $65.90M | (m) | (m) |
| 2012-12-31 | (m) | $62.27M | (m) | (m) |
| 2012-09-30 | (m) | $50.62M | (m) | (m) |
| 2012-06-30 | (m) | $44.14M | (m) | (m) |
| 2012-03-31 | (m) | $36.27M | (m) | (m) |
| 2011-12-31 | (m) | $29.36M | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | $27.29M | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | $20.97M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |